A Study of TAK-071 in People With Parkinson Disease
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
It is hoped that TAK-071 will help people with Parkinson's disease to walk with better
balance. The main aim of the study is to check if there is a difference in how participants
walk after treatment with TAK-071. Another aim is to see if it improves how participants
think and remember.
At the first visit, the study doctor will check who can take part. Participants who can take
part will be picked for 1 of 2 groups by chance.
Both groups will have 2 treatments but in a different order. The treatments are TAK-071
tablets or placebo. In this study, a placebo will look like the TAK-071 but will not have any
medicine in it.
One group will take TAK-071 for 6 weeks, have at least a 3-week break, then take a placebo
for 6 weeks. The other group will take a placebo for 6 weeks, have at least a 3-week break,
then take TAK-071 for 6 weeks. The participants will not know the order of their 2
treatments, nor will their study doctors. This is to help make sure the results are more
reliable.
The participants will visit the clinic at the beginning and end of each treatment for a
check-up. 14 days after the 2nd treatment, clinic staff will telephone the participants for a
final check-up.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda
Collaborator:
Michael J. Fox Foundation for Parkinson's Research